Adjunctive Lisdexamfetamine (LDX) in Bipolar Depression

Adjunctive Lisdexamfetamine in Bipolar Depression

The specific aim of this study is to evaluate the efficacy and tolerability of lisdexamfetamine in the adjunctive treatment of bipolar disorder.

Inclusion Criteria:

• Subjects will meet DSM-IV-TR criteria bipolar I or II disorder,

Exclusion Criteria:

• Women who are pregnant, lactating, or of childbearing potential who are not using adequate contraceptive measures.
• Clinically unstable medical disease, including cardiovascular, hepatic, renal, gastrointestinal, pulmonary, metabolic, endocrine or other systemic disease. Subjects should be biochemically euthyroid to enter the study.